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Among all new emerging RNA species, microRNAs (miRNAs) have attracted
the interest of the scientific community due to their implications as biomarkers
of prognostic value, disease progression, or diagnosis, because of defining fea-
tures as robust association with the disease, or stable presence in easily accessi-
ble human biofluids. This field of research has been established twenty years
ago, and the development has been considerable. The regulatory nature of
miRNAs makes them great candidates for the treatment of infectious diseases,
and a successful example in the field is currently being translated to clinical
practice. This review will present a general outline of miRNAmolecules, as well
as successful stories of translational significance which are getting us closer
from the basic bench studies into clinical practice. 
Uloga mikroRNA u infektivnim bolestima – napredak u zdravstvu
Pregledni rad
Me|u svim novootkrivenim vrstama RNA, mikroRNA(miRNA) su privukle in-
teres znanstvene zajednice zbog svoje mogu}e upotrebe u obliku biomarkera,
njihove prognosti~ke vrijednosti za progresiju bolesti ili u dijagnostici, zbog
sna`ne povezanosti s bolestima i stabilnom prisutno{}u u lako dostupnim ljud-
skim biolo{kim teku}inama. Ovo polje istra`ivanja je utvr|eno prije dvadeset
godina, a njegov razvoj je zapa`en. Regulatorna priroda miRNAih ~ini zna~ajn-
im kandidatima za lije~enje infektivnih bolesti, a uspje{an primjer u tom po-
dru~ju trenutno se prenosi u klini~ku praksu. Ovdje }e biti predstavljen op}i pre-
gled miRNAmolekula, kao i uspje{ne translacijske pri~e prenesene iz temeljnih
istra`ivanja u klini~ku praksu. 
1 Introduction
Since the last 20 years, we have witnessed how the
universe of RNA species has broadened with the discov-
ery of several non protein-coding subtypes (ncRNAs) [1,
2]: small interfering RNAs (siRNAs) [3], microRNAs
(miRNAs) [4, 5], long non-coding RNAs (lncRNAs) [6,
7], RNAi [8], piwiRNA [9], or circular RNAs (circRNAs)
[10]. This review will focus on miRNAs as a class of
ncRNAs with potential clinical applicability due to sever-
al characteristics. Examples of these interesting features
for clinical practice are their higher stability in circulating
biofluids compared with other coding RNAs, and their
close association to a given clinical condition, making
them strong candidates for biomarker discovery. Additio-
nally, they have been studied in the immune system, and
were found to have key roles in signaling, differentiation,
or in response to pathogen. The role of miRNAs in this re-
sponse has been especially addressed, due to the potential
implications for the treatment of infectious diseases.
1.1 General biology of miRNAs
For the reader that comes new to the field, as ubiqui-
tously described and reviewed in literature, small mature
miRNAs molecules range from 18 – 25 nucleotides in
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2 MicroRNAs and diseases
2.1 miRNAs and the immune system
The role of miRNAs in diseases has been addressed in
several studies, which are presented in the following sec-
tion. However, for a good understanding on the impact of
miRNAs over the outcome of the disease, it is basic to un-
derstand how miRNAs influence and regulate different
processes in the immune system. This has been an active
area of research with very good examples of their impor-
tance in shaping the immune system, affecting the devel-
opment of cells such as macrophages [66], B cells [67], or
NK [68, 69], among others.
Macrophages are one of the key cells of the immune
system due to their role during inflammation and posterior
resolution of it. A long lasting inflammation after patho-
genic clearance can have deleterious effects if maintained
in time [70, 71]. Squadrito and collaborators [66] point out
that miRNAs can notably impact and modify all stages of
the macrophage life, from hematopoietic stem cells (HSC)
to macrophage polarization, either to become the proin-
flammatory M1 or the anti-inflammatory M2, showing ev-
idence through extensive literature review to support their
statement. Liu and Abraham [72] discuss further the main
miRNAs that act on each of the polarized states, being
miR-155 a pro-inflammatory miRNA, observation that is
shared in the study of Graff and colleagues [73]. It has been
indicated that miR-155 has the ability to inhibit the M2-
specifying factor [74, 75]. Another example of M1 pro-
moting miRNA is the case of miR-127 [75], reporting the
authors that deletion of this miRNA induced the M2 phe-
notype. The fact that NK cells are under the influence of
miRNA levels, has been reported by Zhang et al., in a
study where they show that bioactivity of NK cells is di-
rectly related with the circulating serum levels of miR-155
[68], results that are also shared by Sullivan and colleagues
[69].
For a coordinated mode of action, any biological sys-
tem must have a mean of communication between its com-
ponents [76, 77], especially if we are considering the im-
mune system. Let's not forget that the system functions in a
coordinated manner as a whole, and not as isolated cells
[76]. This aspect has been covered by Gurwitz in a recent
editorial [78], highlighting that until present most of the
studies concerning miRNAs are performed on the same
cells, what leaves the communication aspect on the road-
side. Not only the miRNAs are endogenous molecules that
modify the response of a cell on its own according to the
environmental or developmental conditions, but also they
serve as key means of communication between cells. That
for example has been demonstrated in immune cells [79],
as well as in other type of tissues or even organisms [80].
The specific referred case of transference in immunity was
reported by Mittelbrun et al. [79], where they show trans-
length [11 – 16], and as described above, they don't encode
for proteins [17, 18]. A key point in their biology that have
attracted the attention of the research community is their
ability to regulate and tune gene [18–20] or protein expres-
sion [21–25], what leads into changes in the target protein
levels [26]. These molecules represent a form of epigenet-
ic regulation and control of the genome [27], and their
mechanisms of action include: blocking of the messenger
RNA (mRNA) [18, 28], directing degradation through a
protein complex [13], or by destabilization of the messen-
ger [29]. There are cases in which a miRNA can up-regu-
late the expression levels of its target as shown by
Vasudevan and colleagues [30]. Whichever the way they
use to alter the outcome, it has been reported that the
recognition of the target occurs through base complemen-
tarity between their 5' end region (seed region), which con-
tains nucleotides 2 to 8, and the mRNA sequence [31, 32].
However there are studies in which, while this comple-
mentarity was not perfect, they still have a regulatory effect
over the messenger [32]. This short sequence recognition
confers a single miRNAthe potential capability to regulate
a number of targets [14, 22, 33, 34], e.g. hsa-let-7a-5p with
several experimentally validated targets [34] such as B-
-cell CLL/lymphoma 2 (BCL2), cell division cycle 25A
(CDC25A), cyclin-dependent kinase 6 (CDK6), dicer 1 ri-
bonuclease type III (DICER1), interleukin 6 (IL6), v-myc
avian myelocytomatosis viral oncogene homolog (MYC),
or NFKB inhibitor interacting Ras-like 2 (NKIRAS2),
among others. In addition to the previous statement, there
are studies that have shown that a single target can be reg-
ulated by multiple miRNAs [14, 15, 35]. It is important to
address that it has been described the existence of a selec-
tive pressure over more than half of the human mRNAs, in
order to keep the pairing capability with miRNAs [31, 36].
Despite being abundant molecules, their expression can be
restricted to a developmental stage [17, 27, 37] or a very
specific environmental condition [38]. An example of the
latter is the recent study from Sturchio et al. [39], carried
out in a human Jurkat leukemic T cell line. In this study the
authors exposed the cells to a chemical form of arsenic,
sodium arsenite, and evaluated their miRNA expression
profile through a microarray platform, having found sig-
nificant differences in expression. Those differences were
subjected to further validation through real time quantita-
tive polymerase chain reaction (RT-qPCR), and some of
the altered miRNAs were miR-221, miR-222, miR-638,
being all up-regulated when compared with the control.
Lastly, miRNAs have been described to be produced in the
nucleus of the cell as a general rule, although some authors
found that mitochondria can also be a source of miRNAs
[40, 41].
All of the above can provide an idea of the reasons why
miRNAs have attracted attention of the scientific commu-
nity, due to their key role as important regulators in the bi-
ological process/functions game [23].
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fer of miRNAs from T-cells to antigen-presenting cells
(APC). They found that the delivery was carried out in ex-
osomes, in a unidirectional manner directed towards the
APC. Besides, those miRNAs were functional and able to
down-regulate genes in the target cell [80]. This is one of
the possible ways, but not restricted to, in which miRNA
communication can occur. Another type of delivery of
miRNAs is mediated through gap junctions (GJs), topic
that is extensively reviewed by Lemcke and co-authors
[81]. GJs mediate delivery of miRNAs of clinical rele-
vance, but as indicated in their review or in previous stud-
ies [82], so far only mature miRNAs are capable of cross-
ing through the channel. This transference can have a se-
lective nature, regarding the type of transported miRNAs,
as it has been shown for human macrophages which were
capable of regulating processes in the receptor cell type, in
this case cancerogenic one, through the delivery of
miRNAs [83]. This represents, according to the authors, a
very important mode of action in the immune cells, besides
cytotoxicity or cytokine production. Another type of cell
communication relevant for the immune system [84] that
may aid in the transference of miRNAs between cells, is
the existence of nanotubes [85], that mediate cell to cell in-
teraction between relatively long distances, considering
the cell size as a reference measurement unit [86].
2.2 Role of miRNAs in infectious diseases
The immune cells act in a coordinated manner, and
miRNA are one of important components for communica-
tion and control. The presence of a pathogenic agent alters
the homeostatic balance of miRNA regulation in several
ways, which can be broadly simplified in two mecha-
nisms: pathogen encoded miRNAs, or alteration of the
host miRNA expression levels.
2.2.1 Pathogen encoded miRNAs
Pathogens encode miRNAs aimed to counterfeit that
ones from the host, thus providing an advantage for the
multiplication and survival of the pathogen. They have
been described for viruses and bacteria.
2.2.1.1 Pathogen encoded miRNAs: Viruses
Pathogen encoded miRNAs were first described for
DNA viruses [87–90], with the first successful report dat-
ing from 2004, in a study in which Pfeffer and collabora-
tors [88] (Table 1.) identified five miRNAs in Epstein-Barr
virus (EBV). The authors characterized the whole set of
small RNAs deriving from a Burkitt's lymphoma cell line
latently infected with EBV, finding that four per cent of the
small RNAs had a viral origin. Further studies covering
miRNAs derived from DNA encoded viruses have been
widely reviewed [91].
It has been argued that this feature was exclusive of
DNA viruses [91, 92], because miRNA expression would
leave RNA genome viruses in a weak position from a bio-
logical fitness perspective [87, 93, 94]. Recent findings are
changing this view [95 – 97], since Kincaid and collabora-
tors [94] (Table 1.) carried out the first study reporting
miRNAs from a virus with a RNA genome, the bovine
leukaemia virus (BLV). Among other studies that have
succeeded in finding viral encoded miRNAs in RNA
genome viruses [98], Hussain et al. [97] (Table 1.) de-
scribed a small regulatory viral RNA (srvRNA), named
KUN-miR-1, which features miRNA properties in West
Nile virus (WNV). They described how viral replication
depends on this miRNA, and that it targets the messenger
of a transcription factor, GATA binding protein 4 (GA-
TA4), determining an increase in the gene messenger accu-
mulation in mosquito cells. In another related study these
authors [99] (Table 1.) were able to identify a miRNA-re-
sembling-candidate in mosquito cells infected with
Dengue virus (DENV). However, this last article raised
questions from other authors, as reflected in a response
from Skalsky et al. [100]. Skalsky and colleagues base
their doubts on a previously reported study from their
group [101], in which they did not find any DENV virus
derived miRNA-like particles through a deep sequencing
approach, and especially pointing to the low expression
values that Hussain and colleagues report on their study as
a major concern for drawing any biologically relevant con-
clusions. In a posterior letter [102], Hussain and Asgari
further addressed those questions from Skalsky, stating
that the advancements in sequencing allow for the discov-
ery of new molecules, despite any previously reported
negative results, or that low-levels of expression of regula-
tory RNAs are not in disagreement with a relevant biolog-
ical function.
Ebola virus (EBOV) has also been described as capa-
ble of encoding miRNAs [95] (Table 1.). The authors of
this study were able to computationally identify two puta-
tive miRNA precursors (pre-miRNAs) and three putative
mature miRNAs. In a further experimental step they trans-
fected HEK293T cells with a plasmid harbouring an
EBOV pre-miRNA construction, and were able to observe
that the host cell machinery was capable to produce the vi-
ral miRNAs [95]. The last example that will be presented
here is that of Hepatitis A virus (HAV). Shi and colleagues
[96], through a combined computational and experimental
approach, demonstrated that HAV can encode miRNAs,
finding a miRNA-like candidate hav-miR-N1-3p, which
can be transcribed in KMB17 and HEK293T cell lines,
leading to the production of the mature form, hav-miR-
N1-3p.
2.2.1.2 Pathogen encoded miRNAs: Bacteria 
In bacteria, the presence of encoded candidate
miRNAs was not reported until 2014 [103, 104]. Within
these two examples, Furuse and colleagues describe a can-
didate miRNA encoded by Mycobacterium marinum
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strain M during the infection of a RAW264.7 murine cell
line [103] (Table 1.); while Shmaryahu and collaborators
[104] (Table 1.), developed a bioinformatics approach to
predict putative miRNAs from 448 different genomes of
pathogenic bacteria. They were able to identify a large
number of candidates and their targets in human mRNAs,
and performed functional studies in transfected human cell
lines, with a construction including the predicted miRNAs,
finding a significant down-regulation of the target expres-
sion [104]. Ren et al. [105] (Table 1.) aimed to characterize
the miRNA profiles between multidrug resistant (MDR)
tuberculosis (TB) and a drug-sensitive TB. Through a
deep-sequencing approach for RNA fractions smaller than
50 nucleotides, they found differential profiles between
both TB strains after an in silico analysis of the sequence
data.
2.2.2 Host altered miRNA profiles
The second mechanism, in which pathogens alter the
system for its own benefit, is the alteration of the host
miRNAs expression levels. It has been described for many
types of infections, either viral or bacterial, with an excel-
lent review for several pathogenic bacteria species in
[106].
2.2.2.1 Host altered miRNA profiles: Viruses
Within the first group, Japanese encephalitis virus
(JEV) is a pathogenic agent that causes acute viral en-
cephalitis. The first report of its infection profile was car-
ried out by Cai et al. [107] (Table 1.), using a JEV-infected
PK-15 cell line (Sus scrofa/pig kidney cell line). In their
study they compared the deep sequencing profile of infect-
ed versus non-infected cells, using an Illumina platform,
having found 1 up-regulated and 6 down-regulated
miRNAs specific for the JEV infection. Other study that
used JEV as pathogen, but this time performed in vitro us-
ing an immortalised human microglial cell line, CHME3,
was reported by Sharma and colleagues [108] (Table 1.). In
their study the authors focused on the profile of miR-146a,
a known anti-inflammatory molecule [109, 110] that tar-
gets the cytokine signalling system through transcriptional
down-regulation of its components IRAK1 and TRAF6
[111]. Besides the in vitro infection of CHME3 cell line,
Sharma and colleagues also tested the effect of the infec-
tion with JEV in either miR-146a over-expressing cells, or
cells in which miR-146a was blocked [108]. The authors
observed an increase in the expression levels of miR-146a
upon JEV infection, what indicates that the virus is using
the post-translational machinery of the cell for its own 
benefit in order to escape the negative effect that the in-
creased inflammation would have over its survival.
Nevertheless, they also indicate that this effects are highly
dependent on the viral strain line, as Pareek et al. report op-
posite results with the same cell type but a different strain
of JEV [112]. It has been previously shown that JEV infec-
tion induces up-regulation in the levels of inflammatory
cytokines [113], such as TNF-α, IL-6, or RANTES [114]
among others, what is aimed to clear the infection, but an
excessive inflammatory response leads to the neurological
damages associated with the disease. In keeping with this
observation, Zhu et al. [113] report an up-regulation of
miR-15b during the infection of JEV in a U251 cell line,
with increased viral clearance when the antagonist is used
in JEV infected mice, suggesting that control of viral-
caused inflammation could be an opportunity for leverag-
ing the clinical symptoms.
Hantavirus (HTV) is another type of virus of clinical
relevance. The host miRNA profile during infection has
been addressed in two recent studies. Shin et al. [115] eval-
uated the distinct miRNA profiles of four hantavirus
strains when infecting three human cell lines (A549, HU-
VEC, and THP-1), through a microarray based platform
[115] (Table 1.). Among their results, the authors highlight
the specific miRNA expression profiles observed depend-
ing either on the host cell type, or on the HTV viral strain.
The following study by Shin et al. [116] carried out a set of
experiments assessing the response to two types of HTV,
Hantaan virus (HTNV) and Imjin virus (MJNV), in a hu-
man astrocytic line (A172), obtaining results in line with
previous reports and suggesting that innate immune re-
sponses occur in brain upon HTV infection. 
Enteroviral infections are caused by a group of viruses
which belong to the genus Enterovirus (EV), as referred
previously [117], causing several type of complications
such as hand-foot-mouth-disease, sepsis-like disease, my-
ocarditis, or hemorrhagic conjunctivitis among others. Wu
et al. have extensively reviewed [118] the current develop-
ment of the field, where it has been reported a central role
of miRNAs in the EV-host interaction.
2.2.2.2 Host altered miRNA profiles: Bacteria
Bacteria are also capable of modifying the host
miRNA levels, as this has been demonstrated in several
studies [119 – 121]. Ma and collaborators evaluated the in-
fluence of a miRNAon the course of bacterial infections in
mice [122] (Table 1.), being the pathogens Listeria mono-
cytogenes or Mycobacterium bovis bacillus Calmette-
Guérin (BCG). They report a lower expression of miR-29
and an enhanced expression of IFN-γ upon infection.
Moreover, they found through further experiments that
miR-29 can target IFN-γ and suppress its production by in-
terfering with the mRNA. Tuberculosis (TB) in humans is
caused by Mycobacterium tuberculosis (MTB), which is
related to the previously mentioned BCG. Zhang et al. [68]
(Table 1.) evaluated the miR-155 expression profiles of TB
infected patients compared to healthy ones, as a potential
way to measure the activity of NK cells in TB patients,
having found a lower expression level in the serum of in-
fected patients. These results could further be used for the
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Table 1. Relevant miRNA studies during the course of different infectious diseases. Studies are divided between those studying
pathogen encoded miRNAs, and reports of altered host miRNA profiles.
Tablica 1. Relevantna istra`ivanja o ulozi miRNA tijekom razli~itih infektivnih bolesti. Istra`ivanja su podijeljena na ona koja



















First reported viral encoded miRNAs Pfeffer et al. [88]
Bovine Leukemia virus
(BLV)
BL3.1 cell line (Bos
taurus), and fetal lamb
kidney (FLK) cell line
First reported RNA virus expressing
miRNAs
Kincaid et al. [94]
West Nile virus (WNV)
Aedes albopictus C6/36
cell line
Viral derived miRNA that controls viral
replication and targets a host mRNA
Hussain et al. [97]
Dengue virus (DENV)
A. aegypti pool, Aag2
cells, A. albopictus
RML-12 line
Identification of a miRNA-resembling can-
didate through a deep sequencing approach
Hussain et al. [99]
Ebola virus (EBOV) HEK293T
Computational identification of two pre-
miRNAs, further functional studies in
HEK293T cell lines






Found the first candidate miRNA from bac-
terial origin, deep sequencing approach
Furuse  et al. [103]




Identification of putative bacterial miRNAs,






Lung tissues from 
affected TB patients












PK-15 cell line (Sus
scrofa)
Deep sequencing miRNA profile alterations
upon infection






Expression changes of the anti-inflammato-








Microarray miRNA based platform; specific
profiles depending on the host cell type, or
the viral strain
Shin et al. [115]





Dysregulated induction of innate immune
genes  due to miRNA expression changes






miR-29 targets IFN-γ, suppression immune
response to intracellular pathogen
Ma et al. [122]
Mycobacterium tuberculosis
Serum from human TB
infected patients
miR-155 expression profiles in serum of in-
fected patients compared with the one from
healthy donors
Zhang et al. [68]
Mycobacterium tuberculosis
complex (MTBC), and a
panel of pathogenic bacteria
Human derived DCs
from healthy donors
Found a core set of 49 miRNAs  expressed
independently of the pathogenic bacteria, or
the time point













General down-regulation on several of the








bacteria and fungi infections
Sepsis patients and
healthy subjects
Microarray miRNA based platform; in-
creased levels of miRNA-155 correlated
with severity of sepsis; lower miR-155 ex-
pression in surviving patients
Liu et al. [129]
Fungus Candida albicans Murine macrophages
Up-regulation of miR-146, miR-155, miR-
455, and miR-125a, induced by heat inacti-
vated bacteria, or LPS exposition





Deregulation of normal miR-146a levels Lukiw et al. [134]
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treatment of TB infections. Siddle et al. [120] (Table 1.)
have also studied the differential miRNA profiles upon
mycobacteria infection in human derived DCs from
healthy donors, using a panel of bacteria that contained
among them three members of the Mycobacterium tuber-
culosis complex (MTBC), with two virulent strains as well
as the BCG strain used by Ma et al. [122]. Siddle and col-
leagues have found a core set of 49 miRNAs that are ex-
pressed in the host cell independently of the bacterial
strain, and which is additionally conserved in time.
Pneumonia caused by Streptococcus pneumoniae has
been studied in mice [123], and it was reported that 
miR-155 is involved in the clearance of the pathogen. In
humans the expression profile of miRNAs in patients af-
fected by pneumonia has been obtained [124] (Table 1.),
where the authors report higher circulating levels for 
miR-21, miR-155, and miR-197.
Schulte et al. [125] (Table 1.) researched the miRNA
alteration in murine RAW 264.7 macrophage-like cell line,
and human HeLa epithelial lines upon infection with
Salmonella enterica serovar Typhimurium, a pathogen
that causes gastroenteritis in humans [126, 127]. Results
include the observation of a general down-regulation on
several of the let-7 family members upon Salmonella in-
fection, independently of the cell type. Through functional
assays the authors were able to show that the targeted let-7
family members can alter the expression of important cy-
tokines, IL-6 and IL-10, having them under negative regu-
lation. The infection was capable to alter this control sys-
tem, leading to an increased cytokine production.
Neisseria meningitidis has been described as a causat-
ive agent for meningitis and fatal sepsis [128]. In a sepsis-
related study, Liu et al. [129] (Table 1.) have used a
miRNA microarray platform as a high-throughput ap-
proach to identify deregulated miRNAs between a group
of healthy controls and sepsis patients, with experimental
validation of an increase in the expression levels of 
miR-155. Furthermore they report that the expression of
this miRNA was positively correlated with the severity of
the disease, and that surviving patients show a lower 
miR-155 expression.
2.2.2.3 Host altered miRNA profiles: Fungi
Candida albicans has been appointed as an important
infectious pathogen in urinary tract infections (UTI) [130].
Monk et al. [131] (Table 1.) described that either heat inac-
tivated Candida albicans or LPS, are able to induce up-
regulation of miR-146, miR-155, miR-455, and miR-125a
in mice macrophages. In the same line of research Li and
colleagues studied the effect of candidemia over mice with
systemic candidiasis, having found a protective effect of
miR-204/miR-211 over the infection associated injuries in
the kidneys. Further studies in human cell lines could give
interesting results if the same trend is found, what poten-
tially can lead to treatment of the infection by restoring
miRNA profiles for these two miRNAs.
2.2.2.4 Host altered miRNA profiles: Prions
Prion diseases [132], have also been studied for
miRNAs presence. This disease is different from those that
have a bacterial or viral origin, due to the self-replicating
nature of the infective particles. It has been addressed by
Shapshak [133], that miRNAs can influence several
processes important for the development of the disease.
Lukiw and collaborators [134] (Table 1.) found a deregula-
tion on the levels of miR-146a, a type of miRNA that is in-
duced in viral infections, in sporadic Creutzfeldt-Jakob
disease (sCJD), suggesting that it is a candidate to be a key
molecule in the regulation of inflammatory brain respons-
es during prion infections.
3 Potential uses as biomarkers
Biomarker can be defined as "a characteristic that is
objectively measured and evaluated as an indicator of nor-
mal biological processes, pathogenic processes, or phar-
macologic responses to a therapeutic intervention", defini-
tion that was proposed at the 1998 National Institutes of
Health Biomarkers Definitions Working Group [42 – 44].
As defined by Weber and collaborators [12], an ideal bio-
marker should comply with non-invasiveness, cheap
quantification methodology, specificity to the disease, reli-
able indication of disease at early stages although no clini-
cal symptoms, and additionally quick procedure; being the
latter of extreme relevance for the diagnostic services at
hospitals, as the physicians must deliver a therapy as soon
as possible.
The uses of miRNAs as biomarkers are diverse, as for
prognossis, early stage identification, diagnosis and strati-
fication, recurrence, pharmacodynamics (PD), or predic-
tion [12, 45 – 47]. They are good candidates for biomark-
ers as they can be measured with a higher sensitivity than
proteins [48], as reported for miRNA-124 in comparison
with alanine aminotransferase (ALT) [49] when evaluat-
ing liver necroinflammation in hepatitis B virus (HBV) in-
fected patients. Their ubiquitous presence in various types
of fluids as blood, saliva, or urine [14, 39, 48, 50], make
them an ideal target in terms of sampling feasibility and
non-invasiveness. Besides, when compared with mRNAs
they show higher stability and decreased degradation rate
in saliva [9, 44, 51], as well as in other biofluids [11]. In
these cases, powerful diagnostic techniques such as 
RT-qPCR are often limited due to the labile nature of RNA
in the provided samples [45]. It cannot be forgotten that
collection of samples in clinical practice is far from the
laboratory research setting, where all environmental vari-
ables are under control, and very importantly sample
freezing or processing can be done immediately upon col-
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lection. That ideal situation is not possible in the clinical
setting, and therefore having such a stable molecule as
miRNAcan offer a significant advantage for the diagnostic
divisions. The importance of biomarkers in PD has been
addressed in a recent review by Gainor et al. [46]. As they
highlight, it is not only important to use predictive bio-
markers in order to aid in the patient selection for the trial,
but also to evaluate the outcome of the drug-target interac-
tion. Indeed, a very good example for that is the previously
mentioned study of Wang et al. [49]. The authors report a
type of miRNA biomarker candidate that can potentially
serve as an indicator of the scale of liver damage in HBV
infected patients, as an alternative to liver biopsy.
Interestingly, the serum miR-124 expression levels varied
accordingly with the levels of necroinflammation. At the
same time, it is a good methodology to evaluate the poten-
tial protective effects of antiviral HBV drugs through 
monitoring of the tissue damage by the levels of miR-124.
Further studies in larger set of patients will be needed for
this promising biomarker in order to reach clinical prac-
tice. 
3.1 Current biomarker or therapeutic uses of 
miRNAs 
In contrast with other examples when the hope in new
technologies exceeds the development of treatments [52],
there are some successful stories in the use of miRNA as
biomarkers or as targets for therapy. This time miRNAs are
closer to the clinical practice. Several companies have
miRNA-based drugs or biomarker assays at different phas-
es of development. Three examples have been selected to
give the reader an idea of the state-of-the-art, and to reflect
three different stages of product development and com-
mercialisation. One active player is a Japanese company
where they follow NGS approaches for the identification
of miRNAs as new biomarkers in non-invasive samples.
Another company in USA is actively developing miRNA
diagnostic platforms, based on their own previous studies
[53 – 55], with a Phase II trial going on for evaluation of a
panel to detect early Alzheimer's disease related miRNAs
in plasma. The last example of the three is an Israeli com-
pany, which is part of a consortium involved in the devel-
opment of new miRNA based therapeutics. Besides, they
commercialize several miRNA diagnostic kits: for cancer
origin detection [56], lung cancer subtype stratification
[57], kidney tumour classification [58], or a test do differ-
entiate mesothelioma from pleura and lung cancers [59].
Lastly, there is a promising example of miRNA thera-
peutical use, as shown in the recent works of Janssen et al.
[60] in subjects affected by chronic HCV infection. This
group have administered a locked nucleic acid-modified
antisense oligonucleotide [61 – 63], Miravirsen, which tar-
gets and binds miR-122 by forming a highly stable 
heteroduplex, what leads to the inhibition of the down-
stream functions of this miRNA. By doing so, they report a
long-lasting viral suppression in the studied individuals,
up to 29 days, what is in accordance with previous studies
in chimpanzees. Very importantly, the target drug was sub-
jected to Phase II clinical trials (identifier No.
NCT01200420) [47, 60, 64, 65].
4 Concluding remarks and future prospects
MicroRNAs are a widely studied set of ncRNAs with
important capabilities over gene and protein expression
regulation and control. They affect a number of processes
according to specific developmental stages or environ-
mental events, and are also key regulators of the human
immune system. Some of their features make them excel-
lent candidates for biomarker discovery, such as a higher
stability in circulating biofluids in comparison to mRNA,
or a close association to a given disease. Despite the need
of all possible advances in different technologies to ad-
dress current challenges in the treatment of diseases, tech-
nological developments are unfortunately not always
quickly translated into clinical developments. MicroRNAs
are currently available in the clinic for the staging and clas-
sification of several cancer diseases due to their consistent
expression profiles. For the field of infectious diseases, it
is a milestone the current Phase II trials for treatment of
HCV. This example will probably encourage other groups
to develop miRNA based strategies for the treatment of in-
fections. 
Targeting pathogen-encoded miRNAs can be a key
point for therapeutic strategies, because a potential inhibi-
tion of their expression or production will interfere with
essential processes for the multiplication and/or replica-
tion of the pathogenic agent. Although it is still quite a
polemic field and further studies are needed, advances in
research provide evidence of miRNAs encoded by bacte-
ria or RNA-genome viruses. A second type of mechanism
is the modification of the host miRNA profiles, as it has
been reported for all types of pathogens, with several im-
portant examples in which miR-155 and miR-146a have
been altered. The current treatment of HCV falls within
this second category, what gives an idea of the potential for
treatment in controlling the fluctuations of host miRNA
expression levels during a process of infection.
In conclusion, miRNA can be used as biomarkers for
the classification of infectious diseases, as well as a target
for the treatment of disease progression.
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